Experience of Using Bedaquiline in a Young Child with Drug Resistant Tuberculosis and Concurrent Primary Immunodeficiency
| Autor: | T. I. Danilova, N. А. Barmina, E. S. Borisova, L. А. Maksimova, Yu. V. Kornev |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2021 |
| Předmět: |
Drug
Pediatrics medicine.medical_specialty Tuberculosis media_common.quotation_subject chemistry.chemical_compound Diseases of the respiratory system children tuberculosis chemotherapy medicine bedaquiline Adverse effect media_common hiv infection Young child RC705-779 business.industry TB chemotherapy General Medicine medicine.disease Multiple drug resistance chemistry Primary immunodeficiency Bedaquiline business multiple drug resistance |
| Zdroj: | Tuberkulez i Bolezni Lëgkih, Vol 99, Iss 8, Pp 47-53 (2021) |
| ISSN: | 2542-1506 2075-1230 |
| Popis: | The article describes a clinical case of the treatment of a young child with a complicated course of tuberculosis with multiple localizations and concurrent primary immunodeficiency. The new anti-tuberculosis drug of bedaquiline was successfully used in the treatment regimen. The child received bedaquiline for 6 months without any adverse events, after 2 months no acid-fast mycobacteria were detected, there were pronounced positive radiological changes which remained until the end of treatment. This clinical case provides evidence that bedaquiline can be used safely and effectively in MDR TB chemotherapy regimens in children under 5 years of age. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|